資本界金控(00204.HK)與河南生命樹生物工程簽訂戰略合作意向書
格隆匯8月12日丨資本界金控(00204.HK)公吿,公司近期與河南生命樹生物工程有限公司("生命樹")簽訂了戰略合作意向書。
生命樹是一家生物工程有限公司,以自主創新為驅動,融合細胞科研、臨牀轉化與產業設備力,構建前沿科技矩陣。自研全自動化設備及醫療器械,破技術壁壘,領航細胞“規模化、標準化製備”新航標。深耕細胞儲存、臨牀研究與藥物研發,定製個性化細胞應用方案,精準迴應多元需求。立行業潮頭,踐科技使命,矢志推動生物科技革新,書寫生命健康華章。
公司認為該等意向書項下擬進行的戰略合作符合集團長期發展目標及業務發展策略。本次與生命樹的戰略合作可為雙方帶來潛在的利潤增長點,此舉符合公司及股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.